The current social, political, and medical role of genetic testing in familial breast and ovarian carcinomas

Current Opinion in Obstetrics and Gynecology

Volumn 11, Issue 1, 1999, Pages 65-70

  Weitzel, Jeffrey N ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HORMONE RECEPTOR; ORAL CONTRACEPTIVE AGENT; RALOXIFENE; TAMOXIFEN;

ARTICLE; BREAST CARCINOMA; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; GENE MUTATION; GENOTYPE; HUMAN; ONCOGENE; ORAL DRUG ADMINISTRATION; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROBABILITY;

BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HEALTH POLICY; HUMANS; OVARIAN NEOPLASMS; UNITED STATES;

EID: 0033025183     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-199901000-00012     Document Type: Article

References (45)

1. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250:1684-1689.
2. Narod SA, Ford D, Devilee P, Barkardottir RB, Lynch HT, Smith SA, et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 1995; 56:254-264.
3. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic •• heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families Am J Hum Genet 1998; 62:676-689 This article nicely summarizes the most complete analysis to date of the BCLC cohort that was so instrumental in identifying BRCA1 and BRCA2, including a reappraisal of estimated penetrance in this highly selected group. It also raises issue of genetic heterogeneity and the possible existence of BRCA3.
4. Malone KE, Daling JR, Thompson JD, O'Brien CA, Francisco LV, Ostrander EA. BRCA1 mutations and breast cancer in the general population J Am Med Assoc 1998; 279.922-929.
5. Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. J Am Med Assoc 1998; 279:915-921.
6. Easton DF, Bishop DT, Ford D, Crockford GP, Consortium BCL. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families Am J Hum Genet 1993; 52:678-701.
7. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE, Breast Cancer Linkage Consortium. Risks of cancer in BRCA1-mutation carriers. Lancet 1994; 343.692-695.
8. Whittemore AS, Gong G, Itnyre J Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer. results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997; 60 496-504
9. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. •• The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336 1401-1408. The first report to suggest a lower penetrance estimate for a large population-based study Risk was still greater than 50% (95% confidence interval, 40-70%), and the wide confidence interval reflects the limitation of sample size (120 carriers identified from an initial pool of 5318 subjects) and admixture of higher and lower risk families. Observation was also restricted to founder mutations so its general applicability is unknown.
10. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991, 48:232-242.
11. Thorlacius S. Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, et al Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998; 352 1337-1339.
12. Ramus SJ, Friedman LS, Gayther SA, Ponder BAJ. A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2. Nature Genet 1996; 15:14-15.
13. Friedman E, Bruchim RBS, Kruglikova A, Risel S, Levylahad E, Halle D, et al. •• Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes Am J Hum Genet 1998; 63:1224-1227. Although this is essentially a case report series, it provides an important lesson regarding the need to screen for all three founder mutations in every Ashkenazi Jewish individual undergoing genetic testing as part of cancer risk assessment. It also provides an interesting observation on BRCA gene biology, suggesting that the effects of BRCA1 and BRCA2 gene mutations are epistatic (not additive).
14. Bar-Sade RB, Kruglikova A, Modan B, Gak E, Hirsh-Yechezkel G, Theodor L, et al. The 185delAG BRCA1 mutation originated before the dispersion of Jews in the Diaspora and is not limited to Ashkenazim. Hum Molec Genet 1998, 7.801-806.
15. Couch F, DeShano ML, Blackwood A, Calzone K, Stopfer J, Campeau L, et al •• BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997; 336:1409-1415. This paper contains the first useful tables for estimating the probability of a detectable BRCA1 mutation in a high-risk clinic population. Key indicators were average age at onset of breast cancer, Ashkenazi Jewish ancestry, the presence of ovarian cancer in the family, and especially the occurrence of both breast and ovarian cancer in an individual. Limitations include the fact that only BRCA1 was assayed and use of the conformation sensitive gel electrophoresis technique, the sensitivity of which has not been compared with sequencing.
16. Frank TS, Manley SA, Olopade OI, Cummings S, Garber J, Bernhardt B, et al. Sequence analysis of BRCA1 and BRCA2. correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998; 16:2417-2425.
17. Parmigiani G, Berry DA, Agiular O. Determining carrier probabilities for breast •• cancer susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998; 62:145-158. The paper describes a model for calculating the probability that a woman is a carrier of a mutation in BRCA1 or BRCA2, on the basis of first and second degree family history. The model incorporates a Bayesian calculation to take into account intra-family relationships and ages of both affected and unaffected members. The main author builds on previous work by his co-author Donald Berry, yielding new tools for cancer risk assessment.
18. Swensen J, Hoffman M, Skolnick MH, Neuhausen SL. Identification of a 14 kb deletion involving the promoter region of BRCA 1 in a breast cancer family. Hum Molec Genet 1997; 6:1513-1517.
19. Puget N, Torchard D, Serova-Sinilnikova OM, Lynch HT, Feunteun J, Lenoir GM, et al A 1-kb alu-mediated germ-line deletion removing BRCA1 exon 17. Cancer Res 1997, 57:828-831.
20. Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drusedau M, et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nature Genet 1997; 17.341-345.
21. Starink TM, Veen JPWVD, Arwert F, Waal LPD, Lange GGD, Gille JJP, et al. The Cowden syndrome a clinical and genetic study in 21 patients. Clin Genet 1986; 29:222-233.
22. Liaw D, Marsh DJ, Li J, Dahia PLM, Wang SI, Zheng Z, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genet 1997; 16:64-67
23. Tsou HC, Teng DH, Ping XL, Brancolini V, Davis T, Hu R, et al. The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. Am J Hum Genet 1987; 61:1036-1043.
24. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia N Engl J Med 1991; 325:1831-1836.
25. Vorechovskii I, Luo L, Lindblom A, Negrini M, Webster DB, Croce CM, et al. ATM mutations in cancer families Cancer Res 1996; 56 4130-4133.
26. Savitsky K, Bar-Shira A, Quad S, Rotman G, Ziv Y, Vanagaite L, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995; 268:1749-1753.
27. FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP, et al Heterozygous ATM mutations do not contribute to early onset of breast cancer Nature Genet 1997; 15:307-310
28. Chen J, Birkholtz GG, Lindblom P, Rubio C, Lindbolm A. The role of ataxia-telangiectasia heterozygotes in familial breast cancer. Cancer Res 1998; 58:1376-1379.
29. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250:1233-1237.
30. Lerman C, Hughes C, Lemon SJ, Main D, Snyder C, Durham C, et al. What you • • don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. J Clin Oncol 1998; 16:1650-1654. In spite of concern about the potential for exacerbating an individual's anxiety by participation in genetic cancer risk assessment, the authors noted adverse psychologic effects in members of BRCA1-linked and BRG42-linked families who decline genetic testing Dr Lerman has conducted several seminal studies of psychosocial aspects of cancer risk assessment.
31. Iglehart JD, Miron A, Rimer BK, Winer EP, Berry D, Shildkraut MJ. Overestimation of hereditary breast cancer risk. Ann Surg 1998; 228:375-384.
32. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin •• WM, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study J Natl Cancer Inst 1998; 90:1371-1388. This paper presents the promising preliminary results from NSABP-P1, one of the largest cancer prevention trials in the history of the National Cancer Institute and cooperative groups. The report highlights the significant reduction in risk for both invasive and non-invasive breast cancers by the use of tamoxifen in women at increased risk for disease. It is important to note the limitations (the subjects not genetically identified so efficacy in BRCA mutation carriers is still unknown) and hazards (a modest increased risk for endometrial cancer and thromboembolic disease) of this trial.
33. Neuhausen SL, Godwin AK, Gershoni-Baruch R, Schubert E, Garber J, •• Stoppa-Lyonnet D, et al. Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet 1998; 62:1381-1388 Interesting observations about the origins of ancient founder mutations, estimated to have arisen 400-2000 years ago. Phenotype analysis supports the existence of an ovarian cancer cluster region (3.3 kb segment of exon 11) associated with a higher risk for ovarian cancer. Methodology for the study was similar to earlier analysis of BRCA1 haplotypes.
34. Gotlieb WH, Friedman E, Bar-Sade RB, Kruglikova A, Hirsh-Yechezkel G, •• Modan B, et al. Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. J Natl Cancer Inst 1998; 90:995-1000. The paper presents an analysis of BRCA founder mutation genotypes among Ashkenazi Jewish women with epithelial ovarian neoplasms. No association was seen between borderline tumors and BRCA mutations providing strong support for the notion of a distinct pathobiology for borderline tumors compared with invasive epithelial ovarian cancer.
35. Malone KE, Daling JR, Weiss NS, McKnight B, White E, Voigt LF. Family history and survival of young women with invasive breast carcinoma. Cancer 1996; 78:1417-1425.
36. Porter DE, Cohen BB, Wallace MR, Smyth E, Chetty U, Dixon JM, et al. Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg 1994; 81:1512-1515.
37. Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollak MN, et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi-Jewish women. Cancer 1997; 80.435-441.
38. Eisinger F, Jacquemier J, Charpin C, Stoppa-Lyonnet D, Bressac-de Paillerets B, Peyrat J-P, et al. Mutations at BRCA1. the medullary breast carcinoma revisited. Cancer Res 1998; 58:1588-1592.
39. Johannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 1998; 16.397-404.
40. Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998; 351:316-321.
41. Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, et al. Recommenda•• tions for follow-up care of individuals with an inherited predisposition to cancer. J Am Med Assoc 1997: 277:997-1003. Consensus recommendations for follow-up care of individuals with BRCAI or BRCA2 mutations was developed by a task force of cancer genetics professionals and practitioners using published evidence-based analyses of specific interventions.
42. Abbott DW, Freeman ML, Holt JT Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 1998; 90:978-985.
43. Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, et al. Oral •• contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998; 339:424-428. Important case-control study of women with BRCA mutations suggesting that the use of oral contraceptives confers a reduction in ovarian cancer risk. The magnitude of the protective effect (60% risk reduction associated with use for six or more years) parallels that seen in the general population.
44. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral-contraceptive use. N Engl J Med 1987; 316.650-655.
45. Ursin G, Henderson BE, Haile RW, Pike MC, Zhou N, Diep A, et al. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res 1997; 57:3678-3681.